Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Download PDF
CC BY-NC-ND 4.0 · Dtsch Med Wochenschr 2021; 146(06): e47-e55
DOI: 10.1055/a-1307-8652
DOI: 10.1055/a-1307-8652
Review
Symptomkontrolle bei Herzinsuffizienzpatienten – was tun bei abfallender GFR und bei Hyperkaliämie?
Symptom control in heart failure patients – how to handle GFR decrease and hyperkalaemia
Zusammenfassung
Bei Patienten mit Herzinsuffizienz und reduzierter Ejektionsfraktion wird durch eine optimierte medikamentöse Therapie sowohl die Symptomkontrolle verbessert als auch die Mortalität gesenkt. Eckpfeiler der Herzinsuffizienztherapie sind dabei Medikamente mit Einfluss auf das Renin-Angiotensin-Aldosteron-System, sogenannte RAAS-Inhibitoren. Dieser Artikel stellt einen kardiologisch-nephrologischen Konsens zur praxisorientierten Hilfestellung bei abnehmender glomerulärer Filtrationsrate oder Anstieg des Serum-Kaliumspiegels vor. Dies sind die 2 häufigsten Gründe für eine Dosisreduktion oder das Absetzen von prognoseverbessernden Medikamenten bei Herzinsuffizienzpatienten.
Abstract
For heart failure patients with reduced ejection fraction, optimised medication improves symptom control and reduces mortality. Substances influencing the renin-angiotensin-aldosteron-system, so-called RAAS-inhibitors, are the cornerstone of heart failure treatment. This article summarises a consensus between experts in cardiology and in nephrology on a pragmatic approach to manage a drop in glomerular filtration rate and incident hyperkalaemia – the two most common reasons for reducing or discontinuing heart failure medication.
Publication History
Article published online:
22 January 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Ponikowski P, Voors AA, Anker SD. et al 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37 (27) 2129-2200 . doi:10.1093/eurheartj/ehw128
- 2 Bundesärztekammer, Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz [Langfassung]. Im Internet (Stand: 19.12.2019): https://www.leitlinien.de/mdb/downloads/nvl/herzinsuffizienz/herzinsuffizienz-3aufl-vers1-lang.pdf
- 3 Rosano GMC, Tamargo J, Kjeldsen KP. et al Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother 2018; 4 (03) 180-188 . doi:10.1093/ehjcvp/pvy015
- 4 Maeder MT, Rickli H, Pfisterer ME. et al Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. Am Heart J 2012; 163 (03) 407-414, 414.e1 . doi:10.1016/j.ahj.2011.12.003
- 5 Clark AL, Kalra PR, Petrie MC. et al Change in renal function associated with drug treatment in heart failure: national guidance. Heart 2019; 105 (12) 904-910 . doi:10.1136/heartjnl-2018-314158
- 6 Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J 2015; 36 (23) 1437-1444 . doi:10.1093/eurheartj/ehv010
- 7 Clark H, Krum H, Hopper I. Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. Eur J Heart Fail 2014; 16 (01) 41-48 . doi:10.1002/ejhf.13
- 8 McCallum W, Tighiouart H, Ku E. et al Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Kidney Int 2019;
- 9 Zhou Y, Hellberg M, Svensson P. et al Sarcopenia and relationships between muscle mass, measured glomerular filtration rate and physical function in patients with chronic kidney disease stages 3–5. Nephrol Dial Transplant 2018; 33 (02) 342-348 . doi:10.1093/ndt/gfw466
- 10 Milic R, Banfi G, Del Fabbro M. et al Serum creatinine concentrations in male and female elite swimmers. Correlation with body mass index and evaluation of estimated glomerular filtration rate. Clin Chem Lab Med 2011; 49 (02) 285-289 . doi:10.1515/CCLM.2011.057
- 11 Aakjaer M, Houlind MB, Treldal C. et al Differences in Kidney Function Estimates Based on Creatinine and/or Cystatin C in Non-Traumatic Amputation Patients and Their Impact on Drug Prescribing. J Clin Med 2019; 8 (01)
- 12 Lima-Oliveira G, Guidi GC, Salvagno GL. et al Estimation of the imprecision on clinical chemistry testing due to fist clenching and maintenance during venipuncture. Clin Biochem 2016; 49 (18) 1364-1367 . doi:10.1016/j.clinbiochem.2016.07.007
- 13 Friedman PA, Scott CG, Bailey K. et al Errors of Classification With Potassium Blood Testing: The Variability and Repeatability of Critical Clinical Tests. Mayo Clin Proc 2018; 93 (05) 566-572 . doi:10.1016/j.mayocp.2018.03.013
- 14 Lee TS, Kim J, Uh Y. et al Correction Equation for Estimation of Actual Potassium Concentration in Hemolyzed Specimen. Clin Lab 2017; 63 (02) 271-275 . doi:10.7754/Clin.Lab.2016.160733
- 15 Aldahl M, Jensen AC, Davidsen L. et al Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 2017; 38 (38) 2890-2896 . doi:10.1093/eurheartj/ehx460
- 16 Bundesärztekammer, Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz. 2. Auflage. Version 3.
- 17 Desai AS, Vardeny O, Claggett B. et al Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol 2017; 2 (01) 79-85 . doi:10.1001/jamacardio.2016.4733
- 18 Salah K, Pinto YM, Eurlings LW. et al Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro-B-type natriuretic peptide levels: An individual patient data analysis. Am Heart J 2015; 170 (03) 531-542.e1 . doi:10.1016/j.ahj.2015.06.003
- 19 Núñez J, Bayés-Genís A, Zannad F. et al Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. Circulation 2018; 137 (13) 1320-1330 . doi:10.1161/CIRCULATIONAHA.117.030576
- 20 Lee Hamm L, Hering-Smith KS, Nakhoul NL. Acid-base and potassium homeostasis. Semin Nephrol 2013; 33 (03) 257-264 . doi:10.1016/j.semnephrol.2013.04.006
- 21 Nash DM, Markle-Reid M, Brimble KS. et al Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study. Nephrol Dial Transplant 2019; 34 (07) 1145-1154 . doi:10.1093/ndt/gfz062
- 22 Waring WS, Stephen AFL, Malkowska AM. et al Acute acetaminophen overdose is associated with dose-dependent hypokalaemia: a prospective study of 331 patients. Basic Clin Pharmacol Toxicol 2008; 102 (03) 325-328 . doi:10.1111/j.1742-7843.2007.00176.x
- 23 Torres OH, Hernandez N, Francia E. et al Effect of prophylactic treatment with low-molecular-weight heparin bemiparin sodium on serum potassium levels: a prospective observational study. Drugs Aging 2010; 27 (05) 399-406 . doi:10.2165/11535440-000000000-00000
- 24 Montford JR, Linas S. How Dangerous Is Hyperkalemia?. JASN 2017; 28 (11) 3155-3165 . doi:10.1681/ASN.2016121344
- 25 Heumann Pharma. Fachinformation Spironolacton. 2016
- 26 Halliday BP, Wassall R, Lota AS. et al Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019; 393: 61-73 . doi:10.1016/S0140-6736(18)32484-X
- 27 Tomson C, Tomlinson LA. Stopping RAS Inhibitors to Minimize AKI. CJASN 2019; 14 (04) 617-619 . doi:10.2215/CJN.14021118
- 28 Mahoney BA, Smith WA, Lo D. et al Emergency interventions for hyperkalaemia. Cochrane Database of Systematic Reviews 2005;
- 29 Noel JA, Bota SE, Petrcich W. et al Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced AgeSerious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate UseSerious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use. JAMA Intern Med 2019; 179 (08) 1025-1033 . doi:10.1001/jamainternmed.2019.0631
- 30 Pitt B, Anker SD, Bushinsky DA. et al Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011; 32 (07) 820-828 . doi:10.1093/eurheartj/ehq502
- 31 Weir MR, Bakris GL, Bushinsky DA. et al Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. NEJM 2015; 372 (03) 211-221 . doi:10.1056/NEJMoa1410853
- 32 Packham DK, Rasmussen HS, Lavin PT. et al Sodium Zirconium Cyclosilicate in Hyperkalemia. N Engl J Med 2014; 372 (03) 222-231 . doi:10.1056/NEJMoa1411487
- 33 Cooper LB, Hammill BG, Peterson ED. et al Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. Circ Cardiovasc Qual Outcomes 2017; 10
- 34 Biesalski HK, Grimm P, Nowitzki-Grimm S. Taschenatlas Ernährung. Thieme Verlag; 2015 6. Aufl..
- 35 Deutsche Gesellschaft für Ernährung e. V. Ausgewählte Fragen und Antworten zu Kalium. Im Internet (Stand: 11/2019): https://www.dge.de/wissenschaft/weitere-publikationen/faqs/kalium/
- 36 Börsteken B. Kalium-Tabelle für pflanzliche Lebensmittel. Im Internet (Stand: 11/2019): https://www.roche.de/pharma/nephrologie/ernaehrung/kaliumtabelle.html
- 37 McCullough PA, Beaver TM, Bennett-Guerrero E. et al Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management. Rev Cardiovasc Med 2014; 15: 11-23 . doi:10.3909/ricm0727
- 38 Zieschang S. Hyperkaliämie im Praxisalltag. Arzneiverordnung in der Praxis 2018; 46 (01) 59-64